News

Prior to joining Kite Pharma, Lee has worked as the vice president of Clinical Development at Syndax Pharmaceuticals. Kite Pharma president and CEO Aya Jakobovits said that he

Prima BioMed has received the status under the generic name Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein (Mucin1- Glutathione S Transferase) Coupled To Oxidised Polymannose for

ALX-0141 Phase I study is a double-blind, placebo-controlled study designed to assess safety, tolerability and PK of a subcutaneous injection of ALX- 0141. The 120 days follow-up of

Signum Biosciences aims to develop novel G-protein coupled receptor (GPCR) modulating therapeutics to treat common skin disorders. Signum intends to use the first SBIR grant to develop anti-inflammatory

Genentech’s information submitted to the FDA during the review of the sBLAs for Avastin for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

The company is planning to commence the construction work from October 2010 and is expected to start operations in the fiscal 2012. In the new plant, the company

In the GFT505-209-4 and GFT505-109-6 studies, GFT505 showed insulin-sensitising effects in non-diabetic subjects. An international expert panel chaired by Bart Staels, president of the Scientific Advisory Board, encouraged

Emergent BioSolutions’ rPA anthrax vaccine candidate is a purified recombinant protective antigen protein formulated with an alum adjuvant and is designed to induce antibodies that neutralise anthrax toxins.

Patients with COPD using the new Onbrez Breezhaler were also able to reduce their use of rescue medication compared to those using salmeterol, a widely prescribed drug in